Antares Pharma

Antares Pharma is a revenue-generating product-focused specialty pharmaceutical company that has developed three proprietary platforms, two of which now include FDA-approved products. Its products typically improve safety and efficacy profiles by minimizing dosing and reducing side effects while improving patient compliance. It focuses on self-injection pharmaceutical products and technologies and topical gel-based products. Its subcutaneous injection technology platforms include Vibex disposable pressure-assisted auto-injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Halozyme Therapeutics

SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), applicable to Halozyme's proposed acquisition of Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") has expired. On April 26, 2022, Halozyme commenced a tender offer (the "Offer") to purchase all outstanding shares of common stock of Antares (the "Shares") for $5.60 per share in cash, without interest thereon and net of any applicable withholding taxes.

Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma

Checkmate Pharmaceuticals

PS Business Parks

Vidler Water Resouces

NEW YORK , May 9, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) 's  sale to Regeneron Pharmaceuticals, Inc. for $10.50 per share in cash. If you are a Checkmate shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CMPI, PSB, ATRS, VWTR

SAN DIEGO , April 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purchaser"), a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") for $5.60 per share in cash. The offer is being made pursuant to the previously announced Agreement and Plan of Merger, dated as of April 12, 2022, by and among Halozyme, Purchaser and Antares (the "Merger Agreement").

HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA

Wilmington, Delaware--(Newsfile Corp. - April 18, 2022) - Rigrodsky Law, P.A. is investigating Antares Pharma, Inc. ("Antares") (NASDAQ: ATRS) regarding possible breaches of fiduciary duties and other violations of law related to Antares' agreement to be acquired by Halozyme Therapeutics, Inc. (NASDAQ: HALO). Under the terms of the agreement, Antares' shareholders will receive $5.60 in cash for each share of Antares common stock they own.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-antares-pharma-inc.To...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Antares Pharma, Inc. Buyout

Antares Pharma (ATRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Antares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?

Origin Bancorp Inc

Sierra Oncology

NEW YORK , April 13, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sierra Oncology , Inc. (NASDAQ: SRRA)'s sale to GlaxoSmithKline plc for $55.00 per share in cash. If you are a Sierra Oncology shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SRRA, ATRS, OBNK

NEW YORK , April 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS), in connection with the proposed acquisition of the Company by Halozyme Therapeutics, Inc. (NASDAQ: HALO) via a tender offer.  Under the terms of the merger agreement, the Company's shareholders will receive $5.60 in cash for each share of Antares common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Antares Pharma, Inc.

Antares Pharma Inc shares (NASDAQ: ATRS) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The deal translates to $5.60 per share for Antares Pharma shareholders that translates to a close to 50% premium on where the stock closed […] The post Antares Pharma Inc shares up 45% on Wednesday: how come?

Antares Pharma Inc shares up 45% on Wednesday: how come?

Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing Antares at approximately $960 million.  The transaction was unanimously approved.

Why Antares Pharma Stock Is Soaring Today

Antares Pharma (ATRS) stock is rocketing higher on Wednesday after the company reached an acquisition agreement with Halozyme (HALO). The post Why Is Antares Pharma (ATRS) Stock Up Today?

Why Is Antares Pharma (ATRS) Stock Up Today?

Agile Therapeutics

Kaleido Biosciences Inc

Here's what you need to know about trading penny stocks on April 13th The post Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes

The drug delivery specialist has reportedly agreed to a merger with Halozyme.

Why Antares Pharma Stock Is Bolting Higher Today

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Antares Pharma, Inc. (NASDAQ: ATRS) to Halozyme Therapeutics, Inc. for $5.60 per share in cash is fair to Antares Pharma shareholders. Halper Sadeh encourages Antares Pharma shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation conce

ATRS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Antares Pharma, Inc. Is Fair to Shareholders

Halozyme will pay $5.60 a share in cash for Antares.

Antares Pharma Stock Soars After $960 Million Halozyme Buyout

Shares of Antares Pharma Inc. ATRS, -0.27% rocketed 46.3% in premarket trading Wednesday toward a two-decade high, after the specialty pharmaceutical company agreed to be acquired by Halozyme Therapeutics Inc. HALO, +0.58% in a cash deal valued at $960 million. Halozyme's stock was still inactive ahead of the open.

Antares Pharma stock rockets after Halozyme buyout deal for a near-50% premium

Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix with Addition of Growing Testosterone Replacement Therapy Product Revenues to Anchor Commercial Opportunity with Key Targeted Audiences Creates a Leading Drug Delivery Business with Broadly Licensable Opportunities across ENHANZE and Antares Auto Injector Platforms Halozyme to Host Conference Call and Webcast Today at 8:00 a.m. ET/5:00 a.m.

Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader

Antares Pharma Inc (NASDAQ: ATRS) has nabbed another FDA approval, and the Company's second involving testosterone. The Company announced FDA approval for Tlando (testosterone undecanoate), an oral treatment for testosterone replacement therapy indicated for deficiency or absence of.

Antares Pharma's Oral Testosterone Treatment Scores FDA Approval

Apple

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript

Antares Pharma (ATRS) delivered earnings and revenue surprises of 100% and 5.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Antares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimates

Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million

Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results

EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Cowen 42nd Annual Healthcare Conference being held on March 7-9, 2022.

Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference

EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens.

Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results

Antares is a company I've followed for years, and I recently decided to reinitiate a position. That's because the stock price has fallen significantly with the broader market while management has made several big moves lately that I really liked.

A Look At Recent Moves By Antares Pharma

The FDA has granted Fast Track designation to Antares Pharma Inc's (NASDAQ: ATRS) for ATRS-1902 for adrenal crisis rescue.  The development program for ATRS-1902 supports a proposed indication of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using Vai proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone.

FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity

EWING, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for ATRS-1902 for adrenal crisis rescue. The development program for ATRS-1902 supports a proposed indication for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our Vai™ novel proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone.

News for Antares Pharma Stock (ATRS)